Laura A. Lane
NED at BioIndustry Association
Greater Oxford Area
Overview
Work Experience
NED
2024 - Current
Vice President - Lilly Ventures (Head of Europe)
2022
Venture Sciences is part of the Lilly New Ventures team. We make strategic direct investment into biotech companies and manage a portfolio of fund-of-fund investments.
Eli Lilly engages in the discovery, development, manufacture, and sale of pharmaceutical products.
Raised $6,500,000.00.
Member Board of Directors
2022
3C is a not-for-profit Community Interest Company (CIC) led by a group of experts with proven backgrounds in antiviral drug discovery, in both pharma and biotech. We propose a new approach to emerging viruses, designed to ensure the world community is better prepared for the epidemics caused by viruses which will inevitably follow COVID-19. Our focus is on developing inhibitors of the viral RNA polymerase complex of coronaviruses, including COVID-19, as a demonstration of a more efficient approach to the problem. https://3ccorona.com/
Principal
2021 - 2022
Joined Advent investing their third life science fund. New investments included: MiroBio (Sold to Gilead Science 2022), Highlight Tx, PIC Therapeutics, Arga Medtech, Proximie. Involved across the full spectrum of investing and portfolio activities. Portfolio support and/or follow-on investments for: Aleta Bio; Alpha Anomeric; Amphista, Artax Biopharma; Aura Biosciences; Epitopea; Iterum Tx; Levicept; Moximed; Nalu Medical; Pheno Tx; Rappta Tx; Tridek-One; Ventus Medical. Established and led pharma outreach and business development activities. Board Director/Observer roles Highlight Tx (Spain), Ventus Medical (UK), Artax BioPharma (US), Aleta Biotherapeutics (US).
Associate
2019 - 2021
Strategy, Business & Corporate Development
2018 - 2022
Leadership and Interim BD and Operational roles at angel and VC-backed biotechs Consultant business development and translational expert for leading global cancer charity
Interim CEO
2018 - 2019
Recruited as CEO for seed stage start-up Aston Particle Technologies (Birmingham). Spinout of Aston University. Transformative and scaled-up drug formulation tech to expand the medicines formulary.
A game-changing dynamics for the manufacturing of drugs.
Raised $1,226,175.00 from DSW Ventures and Aston University.
Interim COO
2018 - 2019
Foresight Williams, Oxford Science Innovation and Oxford Technology backed start-up from University of Oxford Chemistry Department. Mass photometry is a revolutionary new way to measure molecule mass. Company set-up - Operations, Finance, Legal, IT, HR etc. etc.
Co-founder, Director & Chief Operating Officer
2015 - 2018
VirionHealth is developing pioneering therapies for respiratory viral infections through its ground-breaking platform technology. We are the world leader in the development of precisely engineered, non-infectious, defective interfering particles, a new class of biological antiviral that acts by out-competing replication of infectious viruses to both prevent and treat viral infections. The company is focused on prevention and treatment of influenza and respiratory syncytial virus (RSV). Highlights: - Leading $17m Series A from top-tier life science VC and >$4m from DARPA to provide the company with three year plus cash runway to tackle CMC, late preclinical & Phase 1 Clinical Study. - COO responsibilities included set-up, corporate development, project management, legal, outsourcing, intellectual property, facilities, HR and IT.
Business Development
2012 - 2017
Warwick Ventures Ltd mission is to commercialise the world-leading research from the University of Warwick. We create new enterprises and new products, to build both the regional and national economy, as well as aid people’s well-being and support society. Our aim is to realise both the social and the financial impact of the research results generated at Warwick. Focusing predominately on life science and healthcare I managed a large portfolio of IP and spin-out projects through all stages of the technology commercialisation process including IP management, translational research funding, business development, licensing and investment.
Analyst, Analysis & Forecasting
2010 - 2012
Market forecasting, analysis & modelling; market sizing & segmentation; asset valuations; due diligence investigations for in-licensing opportunities; consulting; strategic insights; developing analytical tools and frameworks for epidemiological information; data triangulation exercises for clients in the healthcare, biotechnology and pharmaceutical industries and academic commercialization offices.